Trial
NCT04032158
Study of Evobrutinib in Participants With Relapsing Multiple Sclerosis (RMS)
Phase IIITERMINATEDOTHER/UNKNOWNConfidence: LOW
Sponsor
EMD Serono Research & Development Institute, Inc.
Collaborators
Merck KGaA, Darmstadt, Germany
Condition
Relapsing-remitting Multiple Sclerosis
Intervention
Evobrutinib
Why stopped
Following analysis of open label extension (OLE) data from RMS phase 2 study (MS200527- 0086), it was determined that a change in active comparator warranted in phase 3 RMS comprised of trial MS200527-0073. Consequently, this trial terminated early.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2021-08-05